연구성과로 돌아가기

2023 연구성과별 연구자 정보 (347 / 2675)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Bondarenko, Igor M. Bondarenko, IM 6 Dnipropetrovsk City Multi Field Clin Hosp 4, Dnepropetrovsk, Ukraine U-5156-2017 Bondarenko, Igor 0000-0002-7071-2471 Bondarenko, Igor x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Ahn, Jin-Hee Ahn, JH 7 Asan Med Ctr, Seoul, South Korea C-6122-2019 Ahn, Jin x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Im, Seock-Ah Im, SA 8 Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea J-5620-2012 Im, Seock-Ah x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Litwiniuk, Maria Litwiniuk, M 9 Greater Poland Canc Ctr, Poznan, Poland x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Litwiniuk, Maria Litwiniuk, M 9 Poznan Univ Med Sci, Poznan, Poland x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Shparyk, Yaroslav V. Shparyk, YV 10 Lviv State Oncol Reg Therapeut & Diagnost Ctr, Lvov, Ukraine x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Ho, Gwo Fuang Ho, GF 11 Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia B-8634-2010 HO, GWO FUANG x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Kislov, Nikolay V. Kislov, NV 12 State Budgetary Healthcare Inst Yaroslavl Region, Reg Clin Oncol Hosp, Yaroslavl, Russia x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Wojtukiewicz, Marek Wojtukiewicz, M 13 Bialostockie Cent Onkol Marii Sklodowskiej, Bialystok, Poland x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Sarosiek, Tomasz Sarosiek, T 14 LUX MED Onkol, Warsaw, Poland x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Chae, Yee Soo Chae, YS 15 Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Ahn, Jin Seok Ahn, JS 16 Samsung Med Ctr, Seoul, South Korea x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Jang, Hyerin Jang, H 17 Samsung Bioepis, Incheon, South Korea x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Kim, Sujung Kim, S 18 Samsung Bioepis, Incheon, South Korea x.pivot@icans.eu;
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial Lee, Jiwon Lee, J 19 Samsung Bioepis, Incheon, South Korea x.pivot@icans.eu;
페이지 이동: